NCT03033732View on ClinicalTrials.gov

A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse

PHASE4CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

December 31, 2020

Conditions
Opioid Use Disorder
Interventions
DRUG

Methadone

Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.

DRUG

Buprenorphine-Naloxone

Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.

Trial Locations (7)

T2R 0X7

Calgary Opioid Dependency Program, Calgary

T5J 0G5

Edmonton Opioid Dependency Program, Edmonton

V6Z 1Y6

Rapid Access Addictions Clinic-St. Paul's Hospital, Vancouver

P3C 5K8

Ontario Addiction Treatment Centres- Sudbury Clinic, Greater Sudbury

M6J 1H4

Addiction Medicine Service- Centre for Addictions and Mental Health, Toronto

H2X 0A9

Centre de Recherche du CHUM, Montreal

H2X 1S7

Centre de Recherche et d'Aide pour Narcomane, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Didier Jutras Aswad

OTHER

NCT03033732 - A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse | Biotech Hunter | Biotech Hunter